CTI Heading to FDA Panel

Xconomy Seattle — 

Cell Therapeutics (NASDAQ: CTIC), the Seattle-based developer of pixantrone for non-Hodgkin’s lymphoma, said today that the experimental treatment will be reviewed by an FDA advisory panel on February 10. The FDA’s Oncologic Drugs Advisory Committee will review the evidence for pixantrone and make a recommendation to the agency, which will ultimately decide whether to clear the drug for sale in the U.S. The FDA’s deadline for completing its review of the product is April 23.